Background Children with latent tuberculosis infection (LTBI) represent a huge reservoir for future disease. We wished to determine Mycobacterium tuberculosis (M.tb) infection prevalence among BCG-immunised five-year-old children in Entebbe, Uganda, but there are limited data on the performance of immunoassays for diagnosis of tuberculosis infection in children in endemic settings. We therefore evaluated agreement between a commercial interferon gamma release assay (T-SPOT.TB) and the tuberculin skin test (TST; 2 units RT-23 tuberculin; positive defined as diameter ≥10 mm), along with the reproducibility of T-SPOT.TB on short-term follow-up, in this population. Methodology/Principal Findings We recruited 907 children of which 56 were household contacts of TB patients. They were tested with T-SPOT.TB at age five years and then re-examined with T-SPOT.TB (n = 405) and TST (n = 319) approximately three weeks later. The principal outcome measures were T-SPOT.TB and TST positivity. At five years, 88 (9.7%) children tested positive by T-SPOT.TB. More than half of those that were T-SPOT.TB positive at five years were negative at follow-up, whereas 96% of baseline negatives were consistently negative. We observed somewhat better agreement between initial and follow-up T-SPOT.TB results among household TB contacts (κ = 0.77) than among non-contacts (κ = 0.39). Agreement between T-SPOT.TB and TST was weak (κ = 0.28 and κ = 0.40 for T-SPOT.TB at 5 years and follow-up, respectively). Of 28 children who were positive on both T-SPOT.TB tests, 14 (50%) had a negative TST. Analysis of spot counts showed high levels of instability in responses between baseline and follow-up, indicating variability in circulating numbers of T cells specific for certain M.tb antigens. Conclusions/Significance We found that T-SPOT.TB positives are unstable over a three-week follow-up interval, and that TST compares poorly with T-SPOT.TB, making the categorisation of children as TB-infected or TB-uninfected difficult. Existing tools for the diagnosis of TB infection are unsatisfactory in determining infection among children in this setting.
References
[1]
WHO (2011) Global tuberculosis control: WHO report 2011. Geneva: WHO.
[2]
Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, et al. (2006) Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol 1: 7.
[3]
Cruz AT, Geltemeyer AM, Starke JR, Flores JA, Graviss EA, et al. (2011) Comparing the tuberculin skin test and T-SPOT.TB blood test in children. Pediatrics 127: e31–38.
[4]
Lucas M, Nicol P, McKinnon E, Whidborne R, Lucas A, et al. (2010) A prospective large-scale study of methods for the detection of latent Mycobacterium tuberculosis infection in refugee children. Thorax 65: 442–448.
[5]
Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B (2008) Paediatric tuberculosis. Lancet Infect Dis 8: 498–510.
[6]
Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, et al. (2003) Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361: 1168–1173.
[7]
Lalvani A (2007) Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest 131: 1898–1906.
[8]
Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, et al. (2001) Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 183: 469–477.
[9]
Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, et al. (2001) Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 357: 2017–2021.
[10]
Chee CB, KhinMar KW, Gan SH, Barkham TM, Pushparani M, et al. (2007) Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med 175: 282–287.
[11]
Menzies D, Pai M, Comstock G (2007) Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146: 340–354.
[12]
Joshi R, Narang U, Zwerling A, Jain D, Jain V, et al. (2011) Predictive value of latent tuberculosis tests in Indian healthcare workers: a cohort study. Eur Respir J 38: 1475–1477.
[13]
Shams H, Weis SE, Klucar P, Lalvani A, Moonan PK, et al. (2005) Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med 172: 1161–1168.
[14]
Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, et al. (2007) Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med 4: e192.
[15]
Mutsvangwa J, Millington KA, Chaka K, Mavhudzi T, Cheung YB, et al. (2010) Identifying recent Mycobacterium tuberculosis transmission in the setting of high HIV and TB burden. Thorax 65: 315–320.
[16]
Soysal A, Millington KA, Bakir M, Dosanjh D, Aslan Y, et al. (2005) Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366: 1443–1451.
[17]
Okada K, Mao TE, Mori T, Miura T, Sugiyama T, et al. (2008) Performance of an interferon-gamma release assay for diagnosing latent tuberculosis infection in children. Epidemiol Infect 136: 1179–1187.
[18]
Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, Hatherill M, Moyo S, et al. (2011) The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis. Pediatr Infect Dis J 30: 694–700.
[19]
WHO (2011) Use of tuberculosis interferon gamma release assays (IGRAs) in low- and medium- income countries: Policy statement. Geneva: WHO.
[20]
van Zyl-Smit RN, Zwerling A, Dheda K, Pai M (2009) Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One 4: e8517.
[21]
Pai M, Joshi R, Dogra S, Zwerling AA, Gajalakshmi D, et al. (2009) T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 13: 84–92.
[22]
Herrera V, Perry S, Parsonnet J, Banaei N (2011) Clinical application and limitations of interferon-gamma release assays for the diagnosis of latent tuberculosis infection. Clin Infect Dis 52: 1031–1037.
[23]
Elliott AM, Kizza M, Quigley MA, Ndibazza J, Nampijja M, et al. (2007) The impact of helminths on the response to immunization and on the incidence of infection and disease in childhood in Uganda: design of a randomized, double-blind, placebo-controlled, factorial trial of deworming interventions delivered in pregnancy and early childhood [ISRCTN32849447]. Clin Trials 4: 42–57.
[24]
Anderson EJ, Webb EL, Mawa PA, Kizza M, Lyadda N, et al. (2012) The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. Vaccine 30: 2083–2089.
[25]
Elliott AM, Mawa PA, Webb EL, Nampijja M, Lyadda N, et al. (2010) Effects of maternal and infant co-infections, and of maternal immunisation, on the infant response to BCG and tetanus immunisation. Vaccine 29: 247–255.
[26]
Sauzullo I, Massetti AP, Mengoni F, Rossi R, Lichtner M, et al. (2011) Influence of previous tuberculin skin test on serial IFN-gamma release assays. Tuberculosis (Edinb) 91: 322–326.
[27]
Fine PE, Sterne JA, Ponnighaus JM, Rees RJ (1994) Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet 344: 1245–1249.
[28]
Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33: 159–174.
[29]
Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, et al. (2006) Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med 174: 349–355.
[30]
Pai M, O’Brien R (2007) Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med 4: e208.
[31]
Doberne D, Gaur RL, Banaei N (2011) Preanalytical delay reduces sensitivity of QuantiFERON-TB gold in-tube assay for detection of latent tuberculosis infection. J Clin Microbiol 49: 3061–3064.
[32]
Detjen AK, Loebenberg L, Grewal HM, Stanley K, Gutschmidt A, et al. (2009) Short-term reproducibility of a commercial interferon gamma release assay. Clin Vaccine Immunol 16: 1170–1175.
[33]
Perry S, Sanchez L, Yang S, Agarwal Z, Hurst P, et al. (2008) Reproducibility of QuantiFERON-TB gold in-tube assay. Clin Vaccine Immunol 15: 425–432.
[34]
Barnes PF (2001) Diagnosing latent tuberculosis infection: the 100-year upgrade. Am J Respir Crit Care Med 163: 807–808.
[35]
Codecasa L, Mantegani P, Galli L, Lazzarin A, Scarpellini P, et al. (2006) An in-house RD1-based enzyme-linked immunospot-gamma interferon assay instead of the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection. J Clin Microbiol 44: 1944–1950.
[36]
Ferrara G, Losi M, D’Amico R, Roversi P, Piro R, et al. (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367: 1328–1334.
[37]
Hesseling AC, Mandalakas AM, Kirchner HL, Chegou NN, Marais BJ, et al. (2009) Highly discordant T cell responses in individuals with recent exposure to household tuberculosis. Thorax 64: 840–846.
[38]
Bakir M, Millington KA, Soysal A, Deeks JJ, Efee S, et al. (2008) Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med 149: 777–787.
[39]
Kakkar F, Allen U, Ling D, Pai M, Kitai I (2010) Tuberculosis in children: New diagnostic blood tests. Can J Infect Dis Med Microbiol 21: e111–115.
[40]
Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM (2002) A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 57: 804–809.
[41]
Chee CB, Soh CH, Boudville IC, Chor SS, Wang YT (2001) Interpretation of the tuberculin skin test in Mycobacterium bovis BCG-vaccinated Singaporean schoolchildren. Am J Respir Crit Care Med 164: 958–961.
[42]
Tissot F, Zanetti G, Francioli P, Zellweger JP, Zysset F (2005) Influence of bacille Calmette-Guerin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 40: 211–217.
[43]
Stott H, Patel A, Sutherland I, Thorup I, Smith PG, et al. (1973) The risk of tuberculous infection in Uganda, deprived from the findings of national tuberculin surveys 1958 and 1970. Tubercle 54: 1–22.
[44]
National Tuberculosis and Leprosy Program (2005) Uganda National Program surveillance Report for 2004. Kampala, Uganda.
[45]
Uganda MoH (2006) National Policy Guidelines for TB/HIV Collaborative Activities in Uganda. Ministry of Health.
[46]
Uganda MoH (2010) Manual of the National Tuberculosis and Leprosy Programme. Uganda: Ministry of Health.
[47]
Stein CM, Zalwango S, Malone LL, Won S, Mayanja-Kizza H, et al. (2008) Genome scan of M. tuberculosis infection and disease in Ugandans. PLoS One 3: e4094.
[48]
Migliori GB, Borghesi A, Spanevello A, Eriki P, Raviglione M, et al. (1994) Risk of infection and estimated incidence of tuberculosis in Northern Uganda. Eur Respir J 7: 946–953.
[49]
Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, et al. (2010) Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 59: 1–25.
[50]
Report CCD (2008) Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). Can Commun Dis Rep 34: 1–13.
